VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events
Item 8.01 Other Events.
On April 3, 2019, VBI Vaccines Inc. announced that David Anderson, Ph.D., Chief Scientific Officer, will present the poster, “CMV gB/pp65 eVLPs Formulated with GM-CSF as a Therapeutic Vaccine Against Recurrent Glioblastoma (GBM),” at the 7th International Congenital Cytomegalovirus (CMV) Conference & 17th International CMV Workshop to be held April 7 – 11, 2019 in Birmingham, Alabama. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated April 3, 2019 |
VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop CAMBRIDGE,…
To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
